▲ +86.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $25.50, with a high forecast of $32.00 and a low forecast of $19.00. The average price target represents a 86.00% upside from the last price of $13.71.
The current consensus among 4 investment analysts is to buy stock in Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor's ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.